ImmunoGen, Inc.
NASDAQ: IMGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark Joseph Enyedy
- Employees
- 277
- Headquarters
- Waltham, United States
- IPO year
- 1989
- Market cap
- $8.7B
- Website
- https://www.immunogen.com
Loading IMGN…
Loading profile data…Frequently asked questions about IMGN
What does ImmunoGen, Inc. (IMGN) do?
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients...
Where does IMGN trade?
ImmunoGen, Inc. (IMGN) trades on the NASDAQ Global Select.
What sector is IMGN in?
ImmunoGen, Inc. (IMGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ImmunoGen, Inc.?
Mark Joseph Enyedy is the chief executive officer of ImmunoGen, Inc. (IMGN).
Where is ImmunoGen, Inc. headquartered?
ImmunoGen, Inc. is headquartered in United States.
Does IMGN pay a dividend?
ImmunoGen, Inc. (IMGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMGN go public?
ImmunoGen, Inc. (IMGN) completed its initial public offering in 1989.